KRISTEN GRABLE: Open Payments
NPI 1720001118 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$837 in 45 payments from 10 companies in 2025. Trend: 2023 $546 · 2024 $457 · 2025 $837
Food & beverage: $837
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 19 | $297 |
| Neurocrine BioSciences, Inc. | 9 | $209 |
| Teva Pharmaceuticals USA, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| Alkermes, Inc. | 2 | $37 |
| ABBVIE INC. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: COBENFY, INGREZZA, UZEDY, ABILIFY ASIMTUFII, CAPLYTA, VRAYLAR, LYBALVI, Auvelity.
Industry payments across TX — which companies pay providers there.
